DHDorian Hassoun

Dorian Hassoun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorian Hassoun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GLI Global equations for interstitial lung disease patients: shall we keep the baby, the bathwater or both?

    by Dorian Hassoun, Laurent Plantier, Thomas Gille

    Extract In the past two decades, there have been important developments in the field of reference values for pulmonary function testing. Because of the heterogeneity of lung volumes between human populations, it has long been recommended that lung function laboratories use reference equations derived from the local populations they serve, under the hypothesis that these populations share key genetic characteristics [1]. Although such an approach may have been appropriate when applied to homogeneous populations, its validity was questioned since it was observed that, in populations of mixed ethnic ancestry, some groups of people had significantly different lung volumes. Specifically, population data widely showed that African American subjects, whose ancestry traces back to West Africa, had lower lung volumes than subjects of European ancestry (“Caucasians”).

  • Asthme sévère : mission Rémission

    by D. Hassoun, G. Garcia, L. Guilleminault, C. Dupin

  • L’asthme et l’allergie, rencontres de type 2

    by D. Hassoun, C. Hoarau, C. Nocent-Ejnaini, G. Mahay

  • Open Access

    Allergic Sensitization Driving Immune Phenotyping and Disease Severity in a Mouse Model of Asthma

    by Eléonore Dijoux, Martin Klein, Barbara Misme-Aucouturier, Marie-Aude Cheminant, Marion de Carvalho, Louise Collin, Dorian Hassoun, Erwan Delage, Mathilde Gourdel, Gervaise Loirand, et al.

    Dijoux E, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):246-261. https://doi.org/10.4168/aair.2023.15.2.246


  • Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

    by C. Menigoz, S. Dirou, A. Chambellan, D. Hassoun, A. Moui, A. Magnan, F. X. Blanc

    Introduction: Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations. While the use of FeNO is well established to predict the therapeutic response to dupilumab (anti-IL-4/IL-13), it remains uncertain for biologics targeting the IL-5 pathway. Methods: We conducted an observational, retrospective, monocentric analysis of adults with SEA who started mepolizumab (anti-IL-5) or benralizumab (anti-IL-5-R) between January 1, 2016 and December 31, 2020. Results: Data were collected for 109 patients. All participants reported uncontrolled asthma with a median of 3 annual exacerbations and a median Asthma Control Test score of 12. They all had an initial blood eosinophilia >300/mm3, with a median at 610/mm3 (IQR 420-856). Patients with a baseline FeNO ≥50 ppb reported more exacerbations in the previous year than those with a FeNO <50 ppb (p = 0.02). After initiation of treatment, change in FeNO was not associated with therapeutic response. However, decrease in the annual number of exacerbations was significantly greater in patients with a baseline FeNO ≥50 ppb than in those with a baseline FeNO <50 ppb (-3.3 ± 2.7 vs -0.9 ± 2.4, respectively; p = 0.01). There was no association between baseline FeNO values and subsequent lung function, asthma control or reduction of oral corticosteroids use. Conclusion: In this real-world cohort, adults with SEA who had a baseline FeNO ≥50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5-R biologics than those with a FeNO <50 ppb.


  • Open Access

    Type 2 immunity‐driven diseases: Towards a multidisciplinary approach

    by Dorian Hassoun, Olivier Malard, Sébastien Barbarot, Antoine Magnan, Luc Colas

    Asthma, atopic dermatitis and chronic rhinoconjunctivitis are highly heterogeneous. However, epidemiologic associations exist between phenotypic groups of patients. Atopic march is one such association but is not the only common point. Indeed, beyond such phenotypes, hallmarks of type 2 immunity have been found in these diseases involving immune dysregulation as well as environmental triggers and epithelial dysfunction. From the canonical Th2 cytokines (IL‐4, IL‐5, IL‐13), new cellular and molecular actors arise, from the epithelium's alarmins to new innate immune cells. Their interactions are now better understood across the different environmental barriers, and slight differences appeared. In parallel, the development of type 2‐targeting biotherapies not only raised hope to treat those diseases but also raised new questions regarding their true pathophysiological involvement. Here, we review the place of type 2 immunity in the different phenotypes of asthma, chronic rhinitis, chronic rhinosinusitis and atopic dermatitis, highlighting nuances between them. New hypotheses rising from the use of biotherapies will be discussed along with the uncertainties and unmet needs of this field.